Work

140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC

Year: 2021

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.10.159

Authors: E. Felip, D.R. Spigel, O.J. Juan Vidal, J.T. Beck, C. Aguado de la Rosa, D.H. Johnson, E. Spath-Schwalbe, A. Reinacher-Schick, D. Rodriguez Abreu, M. Altan, N. Reinmuth, M.J. Edelman, M. Reck, Q. Zhao, S. Banerjee, S. Chaudhry, D. Chien, M.A. Tagliaferri, J. Zalevsky, A. Ganti

Institutions: Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Sarah Cannon, Hospital Universitari i Politècnic La Fe, Highlands Oncology Group, Hospital Clínico San Carlos, Ochsner Medical Center, Vivantes Klinikum, Lungenklinik Hemer, Hospital Universitario Insular de Gran Canaria, The University of Texas MD Anderson Cancer Center, Asklepios Fachkliniken München-Gauting, Fox Chase Cancer Center, German Center for Lung Research, LungenClinic Grosshansdorf, Nektar Therapeutics (United States), VA Nebraska Western Iowa Health Care System, University of Nebraska Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4200019923

FWCI: 0.092

Cites:

Cited by: 1

Related to: 10